Exploratory trial on intra-articular etanercept treatment in inflammatory arthritis
Completed
- Conditions
- Rheumatoid arthritisPsoriatic arthritisAnkylosing spondylitisReumatoide artritisArtritis psoriaticaZiekte van Bechterew
- Registration Number
- NL-OMON23874
- Lead Sponsor
- Prof. dr. P.P. Tak, internist-reumatoloogAfd. Klinische immunologie en reumatologieF4-218Meibergdreef 91105 AZ AmsterdamT 020-5662171
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
1. Provision of a written informed consent
2. Age range 18-85
Exclusion Criteria
1. Contra-indication for TNF-blockade
2. Contra-indication for intra-articular treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint of this study is the difference in clinical symptoms of inflammatory arthritis between placebo and intervention group. <br><br>
- Secondary Outcome Measures
Name Time Method The secondary endpoints of this study are (measured at all time points):<br>- Safety endpoints<br>- Acute phase reactants: Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP)<br>- several questionnaires